ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Swedish Orphan Biovitrum AB (PK)

Swedish Orphan Biovitrum AB (PK) (BIOVF)

48,00
0,00
(0,00%)
Fermé 16 Juin 10:00PM

Swedish Orphan Biovitrum AB (PK) (BIOVF) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
48,00
( - )
Prix Achat
30,50
Prix Vente
63,36
Volume échangé
-
0,00 Fourchette du Jour 0,00
27,06 Plage de 52 semaines 48,00
Cap du marché
Clôture Veille
48,00
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 427 392
Actions en circulation
345 845 189
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
166,42
Bénéfice par action (BPA)
2,64
Chiffre d'affairess (LTM)
28,96B
Bénéfice net (LTM)
921M

À propos de Swedish Orphan Biovitrum AB (PK)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers ... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Stockholm, Sweden
Fondé
2026
Swedish Orphan Biovitrum AB (PK) est coté dans le secteur Healthcare de la OTC Markets avec le ticker BIOVF. Le dernier cours de clôture d'Swedish Orphan Biovitrum... (PK) était de US$48,00. Au cours de la dernière année, les actions de Swedish Orphan Biovitrum... (PK) ont été négociées dans une fourchette de prix de US$ 27,06 à US$ 48,00.

Swedish Orphan Biovitrum... (PK) compte actuellement 345 845 189 actions en circulation. La capitalisation boursière d'Swedish Orphan Biovitrum... (PK) est de US$16,60 milliard. Swedish Orphan Biovitrum... (PK) a un ratio cours/bénéfice (ratio PE) de 166.42.

BIOVF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40048484810048CS
128.129920.39096967439.87014839.870110045.55335CS
2611.41531.201312013136.5854836.58512641.33406415CS
5220.89477.082564745827.1064827.0616333.75679867CS
15628.555146.85008999719.4454818.3548727.19299007CS
26029.2515618.754817100222.83582589CS

BIOVF - Frequently Asked Questions (FAQ)

What is the current Swedish Orphan Biovitrum AB (PK) share price?
The current share price of Swedish Orphan Biovitrum AB (PK) is US$ 48,00
How many Swedish Orphan Biovitrum AB (PK) shares are in issue?
Swedish Orphan Biovitrum AB (PK) has 345 845 189 shares in issue
What is the market cap of Swedish Orphan Biovitrum AB (PK)?
The market capitalisation of Swedish Orphan Biovitrum AB (PK) is USD 16,6B
What is the 1 year trading range for Swedish Orphan Biovitrum AB (PK) share price?
Swedish Orphan Biovitrum AB (PK) has traded in the range of US$ 27,06 to US$ 48,00 during the past year
What is the PE ratio of Swedish Orphan Biovitrum AB (PK)?
The price to earnings ratio of Swedish Orphan Biovitrum AB (PK) is 166,42
What is the cash to sales ratio of Swedish Orphan Biovitrum AB (PK)?
The cash to sales ratio of Swedish Orphan Biovitrum AB (PK) is 5,25
What is the registered address of Swedish Orphan Biovitrum AB (PK)?
The registered address for Swedish Orphan Biovitrum AB (PK) is Norra Stationsgatan 93A, Stockholm, Stockholm County
What is the Swedish Orphan Biovitrum AB (PK) website address?
The website address for Swedish Orphan Biovitrum AB (PK) is www.sobi.com
Which industry sector does Swedish Orphan Biovitrum AB (PK) operate in?
Swedish Orphan Biovitrum AB (PK) operates in the Pharmaceuticals sector

BIOVF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock